Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation

Circ Arrhythm Electrophysiol. 2015 Feb;8(1):87-93. doi: 10.1161/CIRCEP.114.002145. Epub 2014 Dec 19.

Abstract

Background: Cardiac sarcoid-related ventricular tachycardia (VT) is a rare disorder; the underlying substrate and response to ablation are poorly understood. We sought to examine the ventricular substrate and outcomes of catheter ablation in this population.

Methods and results: Of 435 patients with nonischemic cardiomyopathy referred for VT ablation, 21 patients (5%) had cardiac sarcoidosis. Multiple inducible VTs were observed with mechanism consistent with scar-mediated re-entry in all VTs. Voltage maps showed widespread and confluent right ventricular scarring. Left ventricular scarring was patchy with a predilection for the basal septum, anterior wall, and perivalvular regions. Epicardial right ventricular scar overlay and exceeded the region of corresponding endocardial scar. After ≥1 procedures, ablation abolished ≥1 inducible VT in 90% and eliminated VT storm in 78% of patients; however, multiple residual VTs remained inducible. Failure to abolish all inducible VTs was because of septal intramural circuits or extensive right ventricular scarring. Multiple procedure VT-free survival was 37% at 1 year, but VT control was achievable in the majority of patients with fewer antiarrhythmic drugs compared with preablation (2.1±0.8 versus 1.1±0.8; P<0.001).

Conclusions: Patients with cardiac sarcoidosis and VT exhibit ventricular substrate characterized by confluent right ventricular scarring and patchy left ventricular scarring capable of sustaining a large number of re-entrant circuits. Catheter ablation is effective in terminating VT storm and eliminating ≥1 inducible VT in the majority of patients, but recurrences are common. Ablation in conjunction with antiarrhythmic drugs can help palliate VT in this high-risk population.

Keywords: arrhythmias, cardiac; catheter ablation; radiofrequency catheter ablation; tachycardia, ventricular.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Arrhythmia Agents / therapeutic use
  • Cardiomyopathies / complications*
  • Cardiomyopathies / diagnosis
  • Catheter Ablation* / adverse effects
  • Combined Modality Therapy
  • Disease-Free Survival
  • Electrophysiologic Techniques, Cardiac
  • Female
  • Heart Conduction System / physiopathology
  • Heart Conduction System / surgery*
  • Heart Ventricles / physiopathology
  • Heart Ventricles / surgery*
  • Humans
  • Male
  • Middle Aged
  • Recurrence
  • Retreatment
  • Sarcoidosis / complications*
  • Sarcoidosis / diagnosis
  • Tachycardia, Ventricular / diagnosis
  • Tachycardia, Ventricular / etiology
  • Tachycardia, Ventricular / physiopathology
  • Tachycardia, Ventricular / surgery*
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Arrhythmia Agents